Treatment optimisation in drug development
Treatment optimisation in drug development
The current drug development paradigm is too drug-centred and does not sufficiently take into account the patients that will receive the new therapy. This has led to the emergence of a research gap between the pre-approval development of medicines and their post-approval use in real-world conditions. In this study, semi-structured interviews were performed with experts in drug development process. It offer an overview concerning the concept of treatment optimisation and potential policy options.
Publication type:
project report
Publication language:
English
Publication date:
2020-03
Publication URL:
https://www.europarl.europa.eu/RegData/etudes/STUD/2020/641511/EPRS_STU(2020)641511_EN.pdf
Institute:
European Parliament / Science and Technology Options Assessment (STOA) (STOA)
Country:
EU
Project:
Treatment optimisation in drug development (STOA)

 Back